Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$205.12 +1.2%	$197.50	$153.58 ▼ $218.66	$362.85B	0.61	5.68 million shs	6.48 million shs
CI The Cigna Group	$324.97 +0.1%	$304.67	$262.03 ▼ $370.83	$88.94B	0.53	1.65 million shs	1.11 million shs
CNC Centene	$59.96 -0.5%	$59.94	$55.03 ▼ $80.59	$29.74B	0.4	4.59 million shs	2.65 million shs
ISRG Intuitive Surgical	$491.84 -3.2%	$556.28	$364.17 ▼ $616.00	$175.18B	1.43	1.52 million shs	1.97 million shs
JNJ Johnson & Johnson	$163.63 +0.3%	$158.68	$140.68 ▼ $169.99	$394.32B	0.47	7.59 million shs	5.76 million shs
LLY Eli Lilly and Company	$820.30 -0.2%	$844.31	$711.40 ▼ $972.53	$777.78B	0.34	3.30 million shs	2.12 million shs
MDT Medtronic	$87.62 -1.5%	$90.98	$75.96 ▼ $96.25	$112.38B	0.8	6.54 million shs	6.32 million shs
PFE Pfizer	$25.20 +0.8%	$26.06	$24.48 ▼ $31.54	$142.93B	0.61	38.88 million shs	32.32 million shs
UNH UnitedHealth Group	$515.47 0.0%	$508.81	$436.38 ▼ $630.73	$471.51B	0.62	4.25 million shs	2.38 million shs
XLV Health Care Select Sector SPDR Fund	$144.52 -0.3%	$146.33	$135.95 ▼ $159.64	$38.15B	0.68	7.48 million shs	6.21 million shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	0.00%	-2.31%	-1.89%	+16.41%	+12.64%
CI The Cigna Group	0.00%	+2.59%	+5.29%	+18.11%	-10.52%
CNC Centene	0.00%	+1.83%	+3.27%	-0.67%	-23.60%
ISRG Intuitive Surgical	0.00%	-0.13%	-14.19%	-6.66%	+23.24%
JNJ Johnson & Johnson	0.00%	+0.14%	-0.97%	+14.16%	+3.44%
LLY Eli Lilly and Company	0.00%	-2.28%	-10.88%	+6.00%	+5.44%
MDT Medtronic	0.00%	-3.04%	-4.76%	+10.06%	+0.54%
PFE Pfizer	0.00%	-3.83%	-4.65%	-4.61%	-9.19%
UNH UnitedHealth Group	0.00%	-0.43%	+8.53%	+1.51%	+4.20%
XLV Health Care Select Sector SPDR Fund	0.00%	-1.42%	-2.96%	+5.30%	-2.17%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABBV AbbVie	4.5161 of 5 stars	2.5	3.0	3.3	3.9	3.5	2.5	1.3
CI The Cigna Group	4.9286 of 5 stars	3.5	4.0	2.5	4.2	4.1	2.5	1.9
CNC Centene	4.7879 of 5 stars	3.3	3.0	0.0	3.7	3.5	1.7	3.8
ISRG Intuitive Surgical	4.5954 of 5 stars	3.3	3.0	0.0	4.0	3.5	2.5	1.9
JNJ Johnson & Johnson	4.4007 of 5 stars	2.3	3.0	4.2	3.9	3.5	2.5	0.6
LLY Eli Lilly and Company	4.8006 of 5 stars	2.4	5.0	3.3	4.0	3.4	2.5	1.9
MDT Medtronic	4.3528 of 5 stars	2.2	4.0	3.3	4.0	2.9	2.5	0.6
PFE Pfizer	4.9866 of 5 stars	3.3	3.0	4.2	4.2	3.3	3.3	3.1
UNH UnitedHealth Group	4.9095 of 5 stars	3.5	3.0	4.2	4.0	3.5	3.3	1.3
XLV Health Care Select Sector SPDR Fund	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABBV AbbVie	2.92	Moderate Buy	$211.45	3.09% Upside
CI The Cigna Group	3.00	Buy	$373.25	14.86% Upside
CNC Centene	2.53	Moderate Buy	$79.92	33.30% Upside
ISRG Intuitive Surgical	2.67	Moderate Buy	$611.86	24.40% Upside
JNJ Johnson & Johnson	2.56	Moderate Buy	$171.33	4.71% Upside
LLY Eli Lilly and Company	2.85	Moderate Buy	$1,009.72	23.09% Upside
MDT Medtronic	2.44	Hold	$96.07	9.65% Upside
PFE Pfizer	2.63	Moderate Buy	$31.92	26.67% Upside
UNH UnitedHealth Group	3.10	Buy	$629.32	22.09% Upside
XLV Health Care Select Sector SPDR Fund	2.76	Moderate Buy	$144.52	N/A

Current Analyst Ratings Breakdown

Latest MDT, ISRG, CI, CNC, PFE, LLY, UNH, JNJ, ABBV, and XLV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/20/2025	CI The Cigna Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$350.00 ➝ $365.00
3/18/2025	ISRG Intuitive Surgical	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$707.00 ➝ $600.00
3/18/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/17/2025	ABBV AbbVie	Erste Group Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/17/2025	ISRG Intuitive Surgical	Erste Group Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
3/17/2025	ISRG Intuitive Surgical	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$666.00 ➝ $605.00
3/12/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/10/2025	JNJ Johnson & Johnson	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/10/2025	PFE Pfizer	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/6/2025	LLY Eli Lilly and Company	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$1,146.00
3/5/2025	ABBV AbbVie	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$210.00 ➝ $240.00

(Data available from 3/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABBV AbbVie	$56.33B	6.44	$15.16 per share	13.53	$1.90 per share	107.96
CI The Cigna Group	$244.38B	0.36	$40.98 per share	7.93	$148.27 per share	2.19
CNC Centene	$163.07B	0.18	$10.15 per share	5.91	$53.42 per share	1.12
ISRG Intuitive Surgical	$8.35B	20.97	$6.48 per share	75.93	$46.41 per share	10.60
JNJ Johnson & Johnson	$88.82B	4.44	$13.45 per share	12.17	$29.69 per share	5.51
LLY Eli Lilly and Company	$45.04B	17.27	$13.37 per share	61.34	$15.05 per share	54.50
MDT Medtronic	$33.20B	3.38	$7.18 per share	12.21	$38.69 per share	2.26
PFE Pfizer	$63.63B	2.25	$3.95 per share	6.38	$15.81 per share	1.59
UNH UnitedHealth Group	$400.28B	1.18	$33.21 per share	15.52	$106.78 per share	4.83
XLV Health Care Select Sector SPDR Fund	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABBV AbbVie	$4.28B	$2.40	85.47	14.67	1.62	7.59%	296.28%	12.65%	4/25/2025 (Estimated)
CI The Cigna Group	$3.43B	$12.24	26.55	9.84	0.98	1.39%	18.61%	4.98%	5/2/2025 (Estimated)
CNC Centene	$3.31B	$6.24	9.61	8.14	0.80	2.03%	13.85%	4.54%	4/25/2025 (Estimated)
ISRG Intuitive Surgical	$2.32B	$6.41	76.73	64.46	5.85	27.81%	14.55%	12.88%	4/22/2025 (Estimated)
JNJ Johnson & Johnson	$14.07B	$6.65	24.61	14.78	2.56	18.20%	34.24%	13.63%	4/15/2025 (Estimated)
LLY Eli Lilly and Company	$10.59B	$11.71	70.05	26.36	1.40	23.51%	85.24%	16.19%	5/1/2025 (Estimated)
MDT Medtronic	$3.68B	$3.29	26.63	15.03	2.22	12.83%	14.07%	7.70%	5/21/2025 (Estimated)
PFE Pfizer	$8.03B	$1.41	17.87	8.32	0.64	12.62%	19.47%	8.09%	4/29/2025 (Estimated)
UNH UnitedHealth Group	$14.41B	$15.50	33.26	15.52	1.37	3.60%	26.69%	8.80%	4/17/2025 (Estimated)
XLV Health Care Select Sector SPDR Fund	N/A	N/A	29.25	∞	N/A	N/A	N/A	N/A	N/A

Latest MDT, ISRG, CI, CNC, PFE, LLY, UNH, JNJ, ABBV, and XLV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/25/2025	N/A	ABBV AbbVie	$2.51	N/A	N/A	N/A	$12.91 billion	N/A
4/25/2025	N/A	CNC Centene	$2.20	N/A	N/A	N/A	$43.16 billion	N/A
4/22/2025	N/A	ISRG Intuitive Surgical	$1.71	N/A	N/A	N/A	$2.19 billion	N/A
4/17/2025	N/A	UNH UnitedHealth Group	$7.24	N/A	N/A	N/A	$111.56 billion	N/A
4/15/2025	N/A	JNJ Johnson & Johnson	$2.59	N/A	N/A	N/A	$21.65 billion	N/A
2/18/2025	Q3 2025	MDT Medtronic	$1.36	$1.39	+$0.03	$1.01	$8.33 billion	$8.29 billion
2/6/2025	Q4 2024	LLY Eli Lilly and Company	$5.45	$5.32	-$0.13	$4.88	$13.42 billion	N/A
2/4/2025	Q4 24	CNC Centene	$0.49	$0.80	+$0.31	$0.56	$38.78 billion	$40.81 billion
2/4/2025	Q4 2024	PFE Pfizer	$0.48	$0.63	+$0.15	$0.07	$17.26 billion	$17.76 billion
1/31/2025	Q4 24	ABBV AbbVie	$2.98	$2.16	-$0.82	-$0.02	$14.81 billion	N/A
1/30/2025	Q4 24	CI The Cigna Group	$7.84	$6.64	-$1.20	$5.13	$63.18 billion	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABBV AbbVie	$6.56	3.20%	+6.04%	273.33%	53 Years
CI The Cigna Group	$6.04	1.86%	+11.87%	49.35%	N/A
CNC Centene	N/A	N/A	N/A	N/A	N/A
ISRG Intuitive Surgical	N/A	N/A	N/A	N/A	N/A
JNJ Johnson & Johnson	$4.96	3.03%	+5.43%	74.59%	63 Years
LLY Eli Lilly and Company	$6.00	0.73%	+15.21%	51.24%	11 Years
MDT Medtronic	$2.80	3.20%	+4.14%	85.11%	48 Years
PFE Pfizer	$1.72	6.83%	+2.50%	121.99%	16 Years
UNH UnitedHealth Group	$8.40	1.63%	+13.46%	54.19%	15 Years
XLV Health Care Select Sector SPDR Fund	$2.29	1.58%	N/A	N/A	N/A

Latest MDT, ISRG, CI, CNC, PFE, LLY, UNH, JNJ, ABBV, and XLV Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/13/2025	ABBV AbbVie	quarterly	$1.64	3.4%	4/15/2025	4/15/2025	5/15/2025
3/6/2025	MDT Medtronic	quarterly	$0.70	3%	3/28/2025	3/28/2025	4/11/2025
1/9/2025	XLV Health Care Select Sector SPDR Fund		$0.5645		3/24/2025	3/24/2025	3/26/2025
1/9/2025	XLV Health Care Select Sector SPDR Fund		$0.5645		3/24/2025	3/24/2025	3/26/2025
1/30/2025	CI The Cigna Group	quarterly	$1.51	2.1%	3/5/2025	3/5/2025	3/20/2025
2/24/2025	UNH UnitedHealth Group	quarterly	$2.10	1.8%	3/10/2025	3/10/2025	3/18/2025
1/2/2025	JNJ Johnson & Johnson	quarterly	$1.24	3.43%	2/18/2025	2/18/2025	3/4/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABBV AbbVie	17.94	0.66	0.55
CI The Cigna Group	0.70	0.66	0.72
CNC Centene	0.70	1.11	1.10
ISRG Intuitive Surgical	N/A	4.07	3.22
JNJ Johnson & Johnson	0.43	1.11	0.86
LLY Eli Lilly and Company	2.00	1.15	0.97
MDT Medtronic	0.48	1.90	1.39
PFE Pfizer	0.63	1.00	0.73
UNH UnitedHealth Group	0.74	0.83	0.91
XLV Health Care Select Sector SPDR Fund	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABBV AbbVie	70.23%
CI The Cigna Group	86.99%
CNC Centene	93.63%
ISRG Intuitive Surgical	83.64%
JNJ Johnson & Johnson	69.55%
LLY Eli Lilly and Company	82.53%
MDT Medtronic	82.06%
PFE Pfizer	68.36%
UNH UnitedHealth Group	87.86%
XLV Health Care Select Sector SPDR Fund	N/A

Insider Ownership

Company	Insider Ownership
ABBV AbbVie	0.25%
CI The Cigna Group	0.70%
CNC Centene	0.33%
ISRG Intuitive Surgical	0.70%
JNJ Johnson & Johnson	0.16%
LLY Eli Lilly and Company	0.13%
MDT Medtronic	0.20%
PFE Pfizer	0.06%
UNH UnitedHealth Group	0.33%
XLV Health Care Select Sector SPDR Fund	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABBV AbbVie	50,000	1.77 billion	1.76 billion	Optionable
CI The Cigna Group	72,500	273.68 million	276.48 million	Optionable
CNC Centene	74,300	496.04 million	494.41 million	Optionable
ISRG Intuitive Surgical	12,100	356.18 million	352.97 million	Optionable
JNJ Johnson & Johnson	152,700	2.41 billion	2.40 billion	Optionable
LLY Eli Lilly and Company	39,000	948.17 million	948.08 million	Optionable
MDT Medtronic	95,000	1.28 billion	1.28 billion	Optionable
PFE Pfizer	83,000	5.67 billion	5.66 billion	Optionable
UNH UnitedHealth Group	400,000	914.71 million	917.25 million	Optionable
XLV Health Care Select Sector SPDR Fund	N/A	263.97 million	N/A	Not Optionable

MDT, ISRG, CI, CNC, PFE, LLY, UNH, JNJ, ABBV, and XLV Headlines

Recent News About These Companies

Waters Corporation Stock: Is WAT Outperforming the Healthcare Sector?

March 26, 2025 | msn.com

Health Care Select Sector SPDR Fund (NYSEARCA:XLV) Stock Price Passes Below Two Hundred Day Moving Average - Time to Sell?

March 26, 2025 | americanbankingnews.com

S&P sector rankings as the first quarter of 2025's close is around the corner

March 24, 2025 | msn.com

3 Sector ETFs & Stocks to Gain Despite Downbeat February Jobs Data

March 14, 2025 | zacks.com

Merck and 8 More Healthcare Stocks for Nervous Dividend Investors

March 13, 2025 | msn.com

Select Sector SPDR ETFs: Strategic Investment with Sector-Specific Allocations

March 12, 2025 | finance.yahoo.com

Recession Fears Looming? Secure Your Portfolio With These ETFs

March 11, 2025 | zacks.com

Health Care Sector Trying to Bounce Back

March 6, 2025 | theglobeandmail.com

Shifting Tides in Leadership: Markets Play Defense

March 6, 2025 | etftrends.com

Time for Defensive Sector ETFs?

February 27, 2025 | zacks.com

Healthcare best performing sector as market angst builds

February 25, 2025 | marketwatch.com

Healthcare Stocks Should Be Hurting. How the Sector Became This Year’s Top Performer.

February 25, 2025 | msn.com

Health Care Has Been a Top Sector

February 22, 2025 | finance.yahoo.com

What Top-Performing Healthcare Funds Are Buying Now

February 19, 2025 | msn.com

Final Trade: FWONK, XLV, MSFT, PEP

February 13, 2025 | youtube.com

18 out of 21 healthcare companies beat profit estimates this week- Earnings scorecard

February 8, 2025 | msn.com

Financials, Health Care Sectors Leading U.S. Stocks Higher In 2025

February 7, 2025 | seekingalpha.com

Stock Market Rotation: To Healthcare (XLV), Then Biotechnology (IBB)

February 6, 2025 | seeitmarket.com

Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?

February 4, 2025 | zacks.com

Can Health Care ETFs Aid Your Portfolio?

February 3, 2025 | etftrends.com

S&P 500 Earnings Set to Shine: January's Critical Market Test (XLV)

December 27, 2024 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
By Jeffrey Neal Johnson | March 21, 2025
View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
Archer Aviation Stock Climbs as Midnight eVTOL Nears Reality
By Jeffrey Neal Johnson | March 10, 2025
View Archer Aviation Stock Climbs as Midnight eVTOL Nears Reality
Occidental Petroleum Drops to 52-Week Low: Buy, Sell, or Hold?
By Thomas Hughes | March 6, 2025
View Occidental Petroleum Drops to 52-Week Low: Buy, Sell, or Hold?
Is BigBear.ai's 25% Plunge a False Alarm or Fire Sale?
By Jeffrey Neal Johnson | March 7, 2025
View Is BigBear.ai's 25% Plunge a False Alarm or Fire Sale?
Why Archer Aviation Stock Could Soar After Palantir Partnership
By Jeffrey Neal Johnson | March 20, 2025
View Why Archer Aviation Stock Could Soar After Palantir Partnership

MDT, ISRG, CI, CNC, PFE, LLY, UNH, JNJ, ABBV, and XLV Company Descriptions

AbbVie NYSE:ABBV

$205.12 +2.40 (+1.18%)

Closing price 03/28/2025 03:59 PM Eastern

Extended Trading

$203.69 -1.43 (-0.70%)

As of 03/28/2025 07:46 PM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

The Cigna Group NYSE:CI

$324.97 +0.23 (+0.07%)

Closing price 03/28/2025 03:59 PM Eastern

Extended Trading

$322.89 -2.08 (-0.64%)

As of 03/28/2025 06:34 PM Eastern

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers. The company's Cigna Healthcare segment offers medical, pharmacy, behavioral health, dental, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as individual health insurance plans; and health care coverage in its international markets, as well as health care benefits for mobile individuals and employees of multinational organizations. In addition, it offers permanent insurance contracts sold to corporations to provide coverage on the lives of certain employees for financing employer-paid future benefit obligations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was formerly known as Cigna Corporation and changed its name to The Cigna Group in February 2023. The Cigna Group was founded in 1792 and is headquartered in Bloomfield, Connecticut.

Centene NYSE:CNC

$59.96 -0.27 (-0.45%)

Closing price 03/28/2025 03:59 PM Eastern

Extended Trading

$60.16 +0.20 (+0.33%)

As of 03/28/2025 07:14 PM Eastern

Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. The company operates through Medicaid, Medicare, Commercial, and Other segments. The Medicaid segment offers health plan coverage, including medicaid expansion, aged, blind, disabled, children's health insurance program, foster care, medicare-medicaid plans, long-term services and support. This segment also provides healthcare products. The Medicare segment offers special needs and medicare supplement, and prescription drug plans. The Commercial segment provides health insurance marketplace product for individual, small, and large group commercials. It also operates clinical healthcare and pharmacies, as well as offers dental and speech therapy services. In addition, the company engages in the government contracts business under the TRICARE program and other healthcare related government contracts. It provides services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in Saint Louis, Missouri.

Intuitive Surgical NASDAQ:ISRG

$491.84 -16.06 (-3.16%)

Closing price 03/28/2025 04:00 PM Eastern

Extended Trading

$490.42 -1.42 (-0.29%)

As of 03/28/2025 07:57 PM Eastern

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. It has a collaboration agreement with FluoGuide A/S for head & neck cancer. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.

Johnson & Johnson NYSE:JNJ

$163.63 +0.50 (+0.31%)

Closing price 03/28/2025 03:59 PM Eastern

Extended Trading

$163.36 -0.27 (-0.17%)

As of 03/28/2025 07:59 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Eli Lilly and Company NYSE:LLY

$820.30 -1.37 (-0.17%)

Closing price 03/28/2025 03:59 PM Eastern

Extended Trading

$815.45 -4.85 (-0.59%)

As of 03/28/2025 07:57 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Medtronic NYSE:MDT

$87.62 -1.36 (-1.53%)

Closing price 03/28/2025 03:59 PM Eastern

Extended Trading

$87.38 -0.23 (-0.27%)

As of 03/28/2025 07:56 PM Eastern

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Pfizer NYSE:PFE

$25.20 +0.19 (+0.76%)

Closing price 03/28/2025 03:59 PM Eastern

Extended Trading

$25.14 -0.07 (-0.26%)

As of 03/28/2025 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

UnitedHealth Group NYSE:UNH

$515.47 -0.25 (-0.05%)

Closing price 03/28/2025 03:59 PM Eastern

Extended Trading

$514.75 -0.72 (-0.14%)

As of 03/28/2025 07:59 PM Eastern

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage. The Optum Health segment provides care delivery, care management, wellness and consumer engagement, and health financial services patients, consumers, care delivery systems, providers, employers, payers, and public-sector entities. The Optum Insight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The Optum Rx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and community health pharmacy services, infusion, and purchasing and clinical capabilities, as well as develops programs in the areas of step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated was founded in 1974 and is based in Minnetonka, Minnesota.

Health Care Select Sector SPDR Fund NYSEARCA:XLV

$144.52 -0.45 (-0.31%)

Closing price 03/28/2025 04:10 PM Eastern

Extended Trading

$144.31 -0.21 (-0.15%)

As of 03/28/2025 07:56 PM Eastern

Health Care Select Sector SPDR Fund (the Fund) seeks to closely match the returns and characteristics of the S&P Health Care Select Sector Index (the Index). The companies included in the Index are selected on the basis of general industry classification from a universe of companies defined by the Standard & Poor's 500 Composite Stock Index (S&P 500). The Health Care Select Sector Index includes companies from the industries, such as pharmaceuticals, healthcare providers and services, healthcare equipment and supplies, biotechnology, life sciences tools and services, and healthcare technology. Under normal market conditions, the Fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the Index. State Street Global Advisors acts as the Fund's investment manager.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MDT, ISRG, CI, CNC, PFE, LLY, UNH, JNJ, ABBV, and XLV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MDT, ISRG, CI, CNC, PFE, LLY, UNH, JNJ, ABBV, and XLV Earnings

Compare Dividends

Latest MDT, ISRG, CI, CNC, PFE, LLY, UNH, JNJ, ABBV, and XLV Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MDT, ISRG, CI, CNC, PFE, LLY, UNH, JNJ, ABBV, and XLV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MDT, ISRG, CI, CNC, PFE, LLY, UNH, JNJ, ABBV, and XLV Company Descriptions

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools